Clinical trials have consistently supported the efficacy and tolerability of semaglutide and other GLP‐1 mimetics, making them a preferred treatment option for individuals intolerant to metformin or requiring reinforced management of type 2 diabetes, obesity, and other diseases. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.